Role of the Endogenous Opioid System Underlying Modulation of Experimental Pain

• Status: Withdrawn
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this proposal is to characterize pain inhibition in healthy controls and Temporomandibular Disorder (TMD) patients with two models of endogenous pain modulation (off-set analgesia; conditioned pain modulation), and to investigate the function of the endogenous opioid system in these responses by using pharmacological blockade of the opioid receptor.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Florida
• Collaborator: American Pain Society
• Treatments: Naltrexone

Criteria

Inclusion Criteria:

• ages 18-50 years old

• Controls: pain-free based on Research Diagnostic Criteria (RDC) exam

• TMD: chronic musculoskeletal pain (face) based on Research Diagnostic Criteria (RDC) exam

Exclusion Criteria:

• Inability to adequately communicate and understand informed consent form;

• Inability to reliably rate pain intensity;

• Uncontrolled hypertension (or receiving treatment for hypertension with BP of greater than 140/95);

• Serious systemic (e.g. Diabetes, thyroid problems, etc.);

• Serious cardiovascular/pulmonary disease;

• Neurological problems with significant changes in somatosensory and pain perception at the intended stimulation sites (hand, foot);

• Serious psychiatric problems requiring treatment (schizophrenia, bipolar disorder);

• Other chronic pain conditions (e.g., low back pain, fibromyalgia);

• Any other ongoing acute pain problem (arthritis, injury-related pain); or,

• Irregular menstrual cycles (>40 days) or menstrual cycle disorders (e.g. PMS, dysmenorrhea).